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ABSTRACT
Introduction: The European Cubicin
Outcomes Registry and Experience (EU-CORESM)
was a retrospective, non-interventional,
multicenter study which evaluated the safety
and effectiveness of daptomycin therapy in
patients with Gram-positive infections
including infective endocarditis (IE).
Methods: Data from the EU-CORE registry were
collected for patients with IE who had received
at least one dose of daptomycin between
January 2006 and April 2012, across 18
countries in Europe (12), Latin America (5)
and Asia (1). Clinical outcomes were assessed
as success (cured or improved), failure or non-
evaluable. Adverse events (AEs) were recorded
during treatment and for up to 30 days post-
treatment; follow-up data were collected for
2 years.
Results: Of 6075 patients included in the EU-
CORE registry, 610 were diagnosed with IE as
primary infection; 149 (24.4%) right-sided IE
(RIE), 414 (67.9%) left-sided IE (LIE), and 47
(7.7%) with both right- and left-sided IE
(BRLIE). Overall clinical success was achieved
in 80.0% of patients (RIE 88.6%, LIE 76.6% and
BRLIE 82.9%). Success rates for methicillin-
resistant Staphylococcus aureus (MRSA)
infections were 90.9%, 71.7% and 66.6% in
patients with RIE, LIE and BRLIE, respectively.
The overall sustained clinical success rate in
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patients followed for up to 2 years was 86.7%
(RIE 93.5%, LIE 88.3% and BRLIE 77.8%). AEs
deemed possibly related to daptomycin in the
investigator’s opinion were reported in 2 (1.3%)
RIE, 18 (4.3%) LIE and 1 (2.1%) BRLIE patients.
There were 11 (1.8%) patients (2 with RIE, 8
with LIE and 1 with BRLIE) with AEs of creatine
phosphokinase elevation reported as possibly
related to daptomycin.
Conclusion: Data from this real-world clinical
setting showed that daptomycin was well
tolerated and effective for the treatment of LIE
and BRLIE in addition to RIE caused by Gram-
positive bacteria, including MRSA. Two-year
follow-up data showed that a high proportion
of patients had a sustained response.
Keywords: Daptomycin; Endocarditis; EU-
CORE; Left-sided endocarditis; Right-sided
endocarditis
INTRODUCTION
Infective endocarditis (IE), primarily caused by
Gram-positive bacteria, is associated with a high
rate of morbidity and mortality, which
represents a large burden to the healthcare
system [1]. Hospitalizations due to IE rose
from 25,511 to 38,976 between 1998 and 2009
in the United States, with increase in serious
neurologic and cardiac complications [2].
Mortality associated with IE ranges between
15% and 20% [2–5].
Although IE is associated with a variety of
microorganisms, staphylococci, streptococci
and enterococci account for the majority of
cases [6]. Staphylococcus aureus is the most
commonly detected causative agent [4, 5]. A
cohort study showed that among 2781 patients
with IE, the most common pathogens were
S. aureus (31%), viridans group streptococci
(17%), enterococci (10%), coagulase-negative
staphylococci (11%), Streptococcus bovis (6%),
and other streptococci (6%) [5].
Methicillin-resistant S. aureus (MRSA) has
emerged as a common pathogen in both
healthcare and community-acquired infections
[7, 8]. Community-acquired MRSA has been
found to be particularly responsible for causing
IE in patients with human immunodeficiency
virus [9]. Another multinational study reported
an increase in the relative proportion of both
hospital- and community-onset of MRSA
bloodstream infections [10]. MRSA infections,
including IE, are associated with higher levels of
mortality compared to methicillin-susceptible
S. aureus (MSSA) [11, 12]. The resistance of
pathogens to commonly used antibiotics is one
of the major public health problems, and the
successful treatment of IE remains challenging.
Patients with IE require an aggressive treatment
approach with effective antibiotics or a
combination of effective antibiotics and
surgery [13–15].
Daptomycin is a bactericidal, cyclic
lipopeptide that is active against Gram-
positive bacteria. The mechanism of action
involves binding (in the presence of calcium
ions) to bacterial membranes of both growing
and stationary phase cells causing
depolarization and leading to a rapid
inhibition of protein, deoxyribonucleic acid
and ribonucleic acid synthesis. This results in
bacterial cell death with negligible cell lysis [16].
Daptomycin is associated with concentration-
dependent activity, hence a high dose of
daptomycin has the ability to penetrate
bacterial biofilm and may help to prevent the
emergence of bacterial resistance [1].
Daptomycin is approved for the treatment of
complicated skin and skin-structure infections
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caused by Gram-positive pathogens, bacteremia
and right-sided IE caused by S. aureus [17, 18].
Infective endocarditis can affect the right side
(RIE), left side (LIE) or both sides (BRLIE) of the
heart. Reports from earlier studies suggest that
daptomycin can be useful in the treatment of
both LIE as well as RIE [18–21], although the drug
is only indicated for use in patients with RIE.
The objective of this analysis from the
European Cubicin Outcomes Registry and
Experience (EU-CORESM) study was to acquire
real-world data on the use and clinical
outcomes of patients who received
daptomycin treatment for IE.
METHODS
Patients and Data Collection
This analysis includes patients enrolled in
EU-CORE, a non-interventional, multicenter,
retrospective, patient registry designed to collect
real-world outcome data on patients who had
received at least one dose of daptomycin for the
treatment of a serious Gram-positive bacterial
infection. The protocol was approved by the
health authority and the Institutional Review
Board (IRB) or Ethics Committee (EC) in each
country and written informed consent was
obtained according to the requirements of the
IRB or EC and/or the local data privacy
regulations. Patients who might have received
daptomycin as part of a controlled clinical trial
were excluded from retrospective collection of
data. Details of the EU-CORE registry have been
published previously [11, 22–24].
The data from the registry were collected
using standardized case report forms for
patients with IE who had received at least one
dose of daptomycin between January 2006 and
April 2012. Supplementary and 2-year follow-up
(until 2014) data were collected for patients
with IE. Patients were included from sites across
18 countries: Argentina, Austria, Brazil,
Bulgaria, Colombia, France, Germany, Greece,
India, Italy, Mexico, Romania, Russia, Slovenia,
Spain, Turkey, United Kingdom, and Venezuela.
Data were collected from the registry for those
patients who received daptomycin treatment
for IE as a primary infection and for whom this
treatment was initiated and completed within
the course of the registry reporting period.
Clinical Outcomes and Safety
Clinical outcomes were assessed by investigators
at the end of therapy as cured, improved, failed,
or non-evaluable according to the following
protocol-defined criteria: cured, clinical signs
and symptoms resolved, no additional
antibiotic therapy was necessary, or infection
cleared with a negative culture reported;
improved, partial resolution of clinical signs
and symptoms and/or additional antibiotic
therapy was warranted; failed, inadequate
response to daptomycin therapy, worsening or
new/recurrent signs and symptoms, need for a
change in antibiotic therapy, or a positive
culture reported at the end of therapy; and
non-evaluable, unable to determine response
due to insufficient information. Clinical success
was defined as outcomes cured or improved.
Time to improvement was also recorded. The
reasons for stopping daptomycin therapy and
other antibiotics prescribed following
daptomycin were also collected [11].
The diagnosis of IE was done according to
modified Duke criteria [25]. The duration of
treatment was estimated as the number of
inpatient and outpatient days the patient
received daptomycin therapy, even if the
treatment was non-consecutive. Long-term
assessments were done after completion of
daptomycin therapy at different follow-up
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visits: 1, 3, 6, 9,12,15,18, 21, and 24 months
and during final follow-up visit. The time to
recurrence or relapse was analyzed using
Kaplan–Meier method for all patients who had
clinical outcomes cured or improved at the end
of daptomycin treatment.
All patients who received at least one dose of
daptomycin were eligible for safety analysis.
Adverse events (AEs) and serious AEs (SAEs)
were recorded during daptomycin treatment
and for 30 days post-treatment. Patients with
IE were further followed for an additional
period of up to 2 years. All reported AEs,
regardless of their relationship to daptomycin,
were recorded and their severity was
determined by the local investigators.
Statistical Analysis
Statistical analysis was performed using
statistical analysis system (SAS) version 9.3
(SAS Institute Inc., Cary, NC, USA). Inferential
analyses were not conducted because of the
nature of the study and no formal statistical
methodology other than simple descriptive
statistics was used. All analyses were
considered to be explanatory.
Numerical variables were summarized as
arithmetic mean, standard deviation, median,
minimum, first quartile, third quartile, and
maximum for continuous variables.
Categorical variables were summarized by
absolute and relative frequencies.
RESULTS
Patient Demographic and Clinical
Characteristics
Out of 6075 patients included in the EU-CORE
registry, 610 (10.0%) were diagnosed with IE
as primary infection, of whom 149 (24.4%)
patients had RIE, 414 (67.9%) patients had LIE
and 47 (7.7%) patients had BRLIE (Table 1).
Supplementary data collected from 272
patients showed the following major and
minor criteria used in the diagnosis of IE:
positive blood culture, 191 (70.2%);
transthoracic echocardiogram, 192 (70.6%),
transesophageal echocardiogram, 158 (58.1%);
predisposing heart condition or intravenous
drug use, 152 (55.9%); fever, 198 (72.8%);
vascular phenomena, 52 (19.1%);
immunologic phenomena, 21 (7.7%); and
serologic evidence, 20 (7.4%). Risk factors for
IE other than predisposing heart condition or
intravenous drug use (55.9%) included vascular
catheter (11.8%) and dental disease or
treatment (7.0%).
Of the total 610 patients, 367 (60.2%)
completed daptomycin therapy without
further antibiotic treatment and 104 (17.0%)
switched to another antibiotic after the end of
daptomycin therapy (e.g., step-down to oral
antibiotic therapy). Patient disposition and
analysis sets are described in Table 1. The
demographics, baseline characteristics and
significant underlying diseases of patients with
IE are summarized in Table 2. The majority of
patients had a significant underlying disease:
133 (89.3%) RIE, 378 (91.3%) LIE and 43
(91.5%) BRLIE. The most common underlying
diseases were cardiovascular, gastrointestinal,
pulmonary, and renal. The majority of patients
with IE were hospitalized prior to receiving
daptomycin treatment (Table 2). The
concomitant use of statins with daptomycin
was reported in 19 (12.8%) RIE, 59 (14.3%) LIE
and 3 (6.4%) BRLIE patients, respectively.
Microbiology
Microbiologic data consisted of culture results
obtained from the study. In total 110 (73.8%)
286 Infect Dis Ther (2015) 4:283–296
RIE, 274 (66.2%) LIE and 29 (61.7%) BRLIE
patients were reported to have positive cultures
(Table 3). MSSA was most commonly identified
in 39 (35.5%), 50 (18.2%) and 7 (24.1%)
patients (RIE, LIE and BRLIE, respectively).
MRSA was identified in 11 (10.0%), 39 (14.2%)
and 3 (10.3%) patients (RIE, LIE and BRLIE,
respectively). Of patients with infections caused
by enterococci, vancomycin-susceptible
Enterococcus faecalis was identified in 5 (4.5%),
30 (10.9%), and 2 (6.9%) patients (RIE, LIE and
BRLIE, respectively). Vancomycin-resistant
Enterococcus faecium was identified in 2 (0.7%)
and 1 (3.4%) patients with LIE and BRLIE,
respectively.
Daptomycin Prescribing Patterns
Among the 610 patients with IE, the most
commonly prescribed dose of daptomycin was
6 mg/kg/day given to 342 (56.1%) patients: 84
(56.4%), 231 (55.8%) and 27 (57.4%) patients
with RIE, LIE and BRLIE, respectively. However,
49 (8%) patients received [6 to\8 mg/kg/day,
109 (17.9%) received C8 to B10 mg/kg/day and
7 (1.1%) patients received [10 mg/kg/day
dose of daptomycin (maximum dose was
12 mg/kg/day in the study), with similar
proportions of RIE, LIE and BRLIE patients
receiving daptomycin dose ranges
[6 mg/kg/day. The median duration for
inpatient therapy was 19 (range 1–81) days, 18
(range 1–112) days and 14 (range 5–72) days for
RIE, LIE and BRLIE, respectively. Of those
treated as inpatients, the median duration of
outpatient follow-up therapy with daptomycin
was 21 (range 7–50) days, 21 (range 5–85) days
and 30 (range 22–75) days for RIE, LIE and
BRLIE, respectively.
Clinical Outcomes
In this retrospective study, data from 610
patients with IE as well as 185 patients with







Infective endocarditis patients in EU-CORE 149 (100) 414 (100) 47 (100)
Completed daptomycin therapy 94 (63.1) 244 (58.9) 29 (61.7)
Primary reason for stopping daptomycin therapy
Switched therapy 36 (24.2) 59 (14.3) 9 (19.1)
Adverse event 4 (2.7) 30 (7.2) 2 (4.3)
Failure 4 (2.7) 17 (4.1) 2 (4.3)
Unable to determine 1 (0.7) 17 (4.1) 2 (4.3)
Other 10 (6.7) 46 (11.1) 3 (6.4)
Unknown – 1 (0.2) –
Entered safety population 149 (100) 414 (100) 47 (100)
Entered efﬁcacy population 149 (100) 414 (100) 47 (100)
BRLIE both right- and left-sided infective endocarditis, EU-CORE European Cubicin Outcomes Registry and Experience,
LIE left-sided infective endocarditis, RIE right-sided infective endocarditis
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Table 2 Demographic and clinical characteristics (safety population)








Median (range) 58.0 (1–90) 62.0 (10–91) 63.0 (24–87)
\65, n (%) 93 (62.4) 227 (54.8) 25 (53.2)
C65, n (%) 56 (37.6) 187 (45.2) 22 (46.8)
C75, n (%) 28 (18.8) 82 (19.8) 16 (34.0)
Sex, n (%)
Female 45 (30.2) 154 (37.2) 17 (36.2)
Male 104 (69.8) 260 (62.8) 30 (63.8)
Race, n (%)
Caucasian 124 (83.2) 355 (85.7) 40 (85.1)
Othera 14 (9.4) 28 (6.8) 2 (4.3)
Unknown 11 (7.4) 31 (7.5) 5 (10.6)
Body weight (kg)
Median (range) 68.0 (6–98) 73.0 (25–120) 70.0 (43–93)
Setting prior to daptomycin therapy, n (%)
Hospital 133 (89.3) 389 (94.0) 43 (91.5)
Nursing home/extended care – – 1 (2.1)
Community 14 (9.4) 24 (5.8) 2 (4.3)
Unknown – – 1 (2.1)
Other 2 (1.3) 1 (0.2) –
Received HMG-CoA reductase inhibitor (statin)
with daptomycin, n (%)
Yes 19 (12.8) 59 (14.3) 3 (6.4)
No 129 (86.6) 354 (85.5) 44 (93.6)
Unknown 1 (0.7) 1 (0.2) –
Severe renal impairment (CrCl\30 mL/min)
at initiation of daptomycin therapy, n (%)
18 (12.1) 76 (18.4) 8 (17.0)
Patients on dialysis at daptomycin initiation, n (%) 13 (8.7) 51 (12.3) 6 (12.8)
Any signiﬁcant underlying diseases ([10% of patients in
every group), n (%)
133 (89.3) 378 (91.3) 43 (91.5)
Cardiovascular disease 93 (62.4) 322 (77.8) 34 (72.3)
Gastrointestinal disease 24 (16.1) 55 (13.3) 7 (14.9)
Pulmonary disease 21 (14.1) 51 (12.3) 9 (19.1)
Renal disease 25 (16.8) 83 (20.0) 12 (25.5)
BRLIE both right- and left-sided infective endocarditis, CrCl creatinine clearance, HMG-CoA 3-hydroxy-3-methylglutaryl-
coenzyme A, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis, SD standard deviation
a Asian, Black and missing
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foreign body intracardiac and 154 patients with
foreign body intravascular device infections
were collected and analyzed.
Of the 610 patients with IE who were treated
with daptomycin, the overall clinical success
rate was achieved in 488 (80.0%) patients. Only
47 (7.7%) patients had a treatment failure
outcome and 75 (12.3%) patients were non-
evaluable. The clinical success rate was achieved
in 142/185 (76.8%) patients with foreign body
Table 3 Primary pathogens in patients with positive cultures
Primary pathogens RIE
N 5 110, n (%)
LIE
N 5 274, n (%)
BRLIE
N 5 29, n (%)
Staphylococcus aureus 53 (48.2) 101 (36.9) 11 (37.9)
Methicillin susceptible 39 (35.5) 50 (18.2) 7 (24.1)
Methicillin resistant 11 (10.0) 39 (14.2) 3 (10.3)
Methicillin susceptibility unknown 3 (2.7) 12 (4.4) 1 (3.4)
Coagulase-negative staphylococci
Staphylococcus epidermidis 30 (27.3) 49 (17.9) 2 (6.9)
Methicillin susceptible 5 (4.5) 5 (1.8) –
Methicillin resistant 22 (20.0) 37 (13.5) 1 (3.4)
Methicillin susceptibility unknown 3 (2.7) 7 (2.6) 1 (3.4)
Other 13 (11.8) 32 (11.7) 6 (20.7)
Methicillin susceptible 3 (2.7) 5 (1.8) 1 (3.4)
Methicillin resistant 10 (9.1) 25 (9.1) 2 (6.9)
Methicillin susceptibility unknown – 2 (0.7) 3 (10.3)
Staphylococcus species—coagulase not speciﬁed 1 (0.9) 2 (0.7) –
Enterococcus faecium – 7 (2.6) 1 (3.4)
Vancomycin susceptible – 3 (1.1) –
Vancomycin resistant – 2 (0.7) 1 (3.4)
Vancomycin susceptibility unknown – 2 (0.7) –
Enterococcus faecalis 6 (5.5) 34 (12.4) 3 (10.3)
Vancomycin susceptible 5 (4.5) 30 (10.9) 2 (6.9)
Vancomycin susceptibility unknown 1 (0.9) 4 (1.5) 1 (3.4)
Other Enterococcus species – 7 (2.6) –
Streptococcus agalactiae or group B streptococci 1 (0.9) 2 (0.7) –
Streptococcus dysgalactiae – 1 (0.4) –
Streptococcus dysgalactiae equisimilis – 1 (0.4) –
Streptococcus pneumonia – 1 (0.4) –
Streptococcus pyogenes or group A streptococci – 2 (0.7) –
Streptococcus species 3 (2.7) 9 (3.3) 1 (3.4)
Viridians streptococci group 3 (2.7) 18 (6.6) 2 (6.9)
Gram-negative bacilli – 2 (0.7) 1 (3.4)
Gram-positive cocci – 2 (0.7) 1 (3.4)
Othera – 4 (1.5) 1 (3.4)
BRLIE both right- and left- sided infective endocarditis, LIE left-sided infective endocarditis, RIE right-sided infective endocarditis
a Includes Corynebacterium species
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intracardiac device infection and 120/154
(77.9%) patients with foreign body
intravascular device infection.
Clinical success rate was achieved in 132
(88.6%), 317 (76.6%) and 39 (83.0%) patients
with RIE, LIE and BRLIE infections, respectively
(Fig. 1). Treatment failure rates were low
(4.3–8.7%) across all types of IE. Clinical
success rate in 107 (92.2%) patients treated
with daptomycin doses C8 mg/kg/day was
higher compared with lower doses. There was
a trend towards higher rates of success as
daptomycin doses increased (Table 4). Patients
with RIE, LIE and BRLIE who had received a
daptomycin dose of 6 mg/kg/day had a median
of 5 (range 1–46) days, 4 (range 1–41) days and
4.5 (range 0–16) days of time to improvement.
Clinical success rate was achieved in 46/53
(86.8%) RIE, 79/101 (78.2%) LIE and 10/11
(90.9%) BRLIE patients with infections caused
by S. aureus. High rates of clinical success were
reported in patients who had MSSA and MRSA
infections. Patients with RIE achieved 87.1%
(n = 34) and 90.9% (n = 10) success, patients
with LIE 84.0% (n = 42) and 71.8% (n = 28)
success, and patients with BRLIE 100% (n = 7)
and 66.7% (n = 2) success against MSSA and
MRSA infections, respectively. Clinical success
was achieved in 96.7% (n = 30) RIE, 79.6%
(n = 49) LIE and 100% (n = 2) BRLIE patients
with infections caused by Staphylococcus
epidermidis. Surgical interventions such as
replacement of heart valves and removal of
foreign devices were also required for the
management of patients with IE. In 21 (14.1%)
RIE, 166 (40.1%) LIE and 11 (23.4%) BRLIE
patients heart valves were replaced; whereas in
37 (24.8%) RIE and 14 (3.4%) LIE patients
foreign devices were surgically removed.
Of 272 patients, who had supplementary
data collected, the most common surgical
procedures during daptomycin treatment were
heart valves replaced in 57 (21.0%), foreign
intracardiac device removed in 14 (5.1%), tissue
debridement in 6 (2.2%), vascular graft


































Fig. 1 Clinical outcomes in patients with infective endo-
carditis. BRLIE both right- and left-sided infective
endocarditis, LIE left-sided infective endocarditis, RIE
right-sided infective endocarditis












All 23/38 (60.5) 32/46 (69.6) 280/342 (81.9) 37/49 (75.5) 107/116 (92.2)
Right sided 5/7 (71.4) 11/11 (100) 73/84 (86.9) 11/11 (100) 32/34 (94.1)
Left sided 15/28 (53.6) 18/31 (58.1) 185/231 (80.1) 23/35 (65.7) 68/74 (91.9)
Both right and left sided 3/3 (100) 3/4 (75.0) 22/27 (81.5) 3/3 (100) 7/8 (87.5)
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and drainage in 2 patients (0.7%). Surgical
procedures performed within 60 days after
stopping treatment with daptomycin were:
heart valves replaced in 11 (4.0%), foreign
intracardiac device removed in 3 (1.1%) and
tissue debridement in 1 (0.4%) patient. Of
the patients who underwent heart valve
replacement during or after stopping
daptomycin therapy, 65.9% had this
procedure done by day 14 from start of
daptomycin, 81.8% by day 30 and 100% by
day 90.
The sustained clinical success rate in 211
patients with IE and/or foreign body
intracardiac/intravascular device infection who
were followed for up to 2 years was 86.7%
(93.5% for RIE, 88.3% for LIE and 77.8% for
BRLIE). The majority (86.2%) of these patients
remained relapse free at the end of the 2-year
follow-up period (Fig. 2).
Safety
An overview of AEs is presented in Table 5.
Overall, 5 (3.4%), 30 (7.2%) and 2 (4.3%)
patients with RIE, LIE and BRLIE discontinued
daptomycin therapy due to AEs, respectively.
The numbers of reported AEs which were
related to daptomycin were low: 2 (1.3%) in
patients with RIE, 18 (4.3%) in patients with
LIE, and 1 (2.1%) patients with BRLIE. Among
AEs reported as related to daptomycin, creatine
phosphokinase (CPK) elevation was observed in
2 (1.3%), 8 (1.9%) and 1 (2.1%) patients, with
RIE, LIE and BRLIE, respectively. Two patients
(LIE) developed eosinophilic pneumonia. Death
was reported in 5 (3.4%), 53 (12.8%) and 7
(14.9%) patients with RIE, LIE and BRLIE,
respectively; none of the SAEs associated with
deaths were considered to be related to
daptomycin.
Fig. 2 Kaplan–Meier survival curve for patients with infective endocarditis and/or foreign body intracardiac/intravascular
device infection with long-term follow-up
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DISCUSSION
Infective endocarditis is a complex infection
which can present in different ways, which vary
according to the initial clinical manifestation,
underlying cardiac disease, associated
pathogen, and the presence of any
complications. The incidence of IE and its
Table 5 Summary of adverse events (safety population)
Safety parameters RIE
N5 149, n (%)
LIE
N5 414, n (%)
BRLIE
N5 47, n (%)
AEs 16 (10.7) 98 (23.7) 10 (21.3)
SAEs 9 (6.0) 70 (16.9) 10 (21.3)
Discontinuations due to AEs 5 (3.4)) 30 (7.2) 2 (4.3)
AEs possibly related to daptomycin, n (%) 2 (1.3) 18 (4.3) 1 (2.1)
Blood CPK increased 2 (1.3) 8 (1.9) 1 (2.1)
Myalgia 1 (0.7) – –
Agranulocytosis – 1 (0.2) –
Eosinophilia – 1 (0.2) –
Eye pain – 1 (0.2) –
Mouth ulceration – 1 (0.2) –
Cholestasis – 1 (0.2) –
Pneumonia – 1 (0.2) –
Rhabdomyolysis – 1 (0.2) –
Eosinophilic pneumonia – 2 (0.5) –
Pulmonary interstitial emphysema syndrome – 1 (0.2) –
Dermatitis allergic – 1 (0.2) –
Rash – 1 (0.2) –
Rash generalized – 1 (0.2) –
SAEs possibly related to daptomycin, n (%) – 6 (1.4) –
Agranulocytosis – 1 (0.2) –
Cholestasis – 1 (0.2) –
Blood CPK increased – 2 (0.5) –
Rhabdomyolysis – 1 (0.2) –
Eosinophilic pneumonia – 2 (0.5) –
Pulmonary interstitial emphysema syndrome – 1 (0.2) –
Rash generalized – 1 (0.2) –
AE adverse event, BRLIE both right- and left- sided infective endocarditis, CPK creatine phosphokinase, LIE left-sided
infective endocarditis, RIE right-sided infective endocarditis, SAE serious AE
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mortality have not decreased in the past
30 years. Although there were major advances
in diagnostic and therapeutic procedures, the
disease still carries a poor prognosis and a high
mortality [26]. The present retrospective
analysis from the EU-CORE patient registry
provides valuable information on real-life
experience of patients with IE who were
treated with daptomycin across multiple
centers from 18 countries, which may not
otherwise be apparent from a randomized
clinical trial.
Data from this analysis demonstrate that
daptomycin was successful for the treatment of
patients with IE caused by Gram-positive
bacteria, including MRSA. This finding is
consistent with the earlier published reports
[11, 27]. Overall, clinical success rates were
high, demonstrating effective use of
daptomycin to treat IE.
In this analysis, there was a trend towards
higher success rate with higher daptomycin
doses C8 mg/kg/day (maximum dose was
12 mg/kg/day) compared with lower doses.
This was consistent with a previous report
[21]. Hence, the use of higher doses of
daptomycin C8 mg/kg/day may result in better
treatment outcome against IE. This supports
recommendations from international treatment
guidelines for the use of higher doses of
daptomycin in the treatment of patients with
IE [1, 28]. Further exploratory analyses will be
required to assess outcome by patients
underlying disease status, and whether
treatment was administered as first or second
line.
Data from 414 patients with LIE were
collected and analyzed in this analysis. The
results were similar to those of 149 patients with
RIE and 47 patients with BRLIE. In an
observational cohort study, out of 178 patients
with LIE, 29 received daptomycin and 149
received standard-of-care (SOC) therapy (e.g.,
penicillins, vancomycin, ampicillin,
aminoglycosides). There was a trend towards
better outcome with higher doses of
daptomycin compared to SOC therapy for
patients with LIE [21], which is consistent
with our findings. Although daptomycin is not
currently approved for the treatment of LIE,
data from the present analysis have shown that
daptomycin was used successfully for the
treatment of LIE and BRLIE with a trend
towards higher clinical success rates with
higher daptomycin doses. Therefore, data from
this analysis suggest that daptomycin may be
effective for the treatment of LIE and BRLIE.
The most commonly encountered causative
agent was S. aureus, followed by S. epidermidis.
There was a higher proportion of enterococcal
infection in patients with LIE than in RIE and
BRLIE. Also, there was a broader range of
streptococcal infections in LIE than in RIE or
BRLIE. In this study, MSSA was more commonly
isolated than MRSA from patients with IE.
Patients with IE who had complicated MSSA
and MRSA infections and received daptomycin
therapy had high success rates. These results are
consistent with the findings from an earlier
in vitro study on IE model which showed that
daptomycin had better bactericidal activity
against the biofilm-forming MRSA compared
with vancomycin [29]. Data from a prospective
cohort study reported that the mortality of
patients with IE infections caused by MRSA
isolates was high with vancomycin minimum
inhibitory concentration of 2 mg/L (determined
by Etest) [30]. Daptomycin at higher doses may
be considered as first-line therapy to manage
both MSSA and MRSA infections in patients
with IE, which was also mentioned in an earlier
published report [31]. In an in vitro study, it was
observed that daptomycin in combination with
b-lactams enhanced efficacy of anti-MRSA
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therapeutic options against daptomycin-
resistant MRSA infections [32]. The results of
another in vitro study showed that the
combination of high doses of daptomycin
with fosfomycin was effective in the treatment
of left-sided endocarditis (both native and
prosthetic valves) caused by MSSA or MRSA
infections [33]. In the present study, the notable
finding was that the clinical success rates
remained high in patients with reported long-
term follow-up results for up to 2 years.
This study has limitations due to its
retrospective and non-comparative design. It
was not as strictly controlled as a randomized
controlled trial. Analysis was not conducted to
provide statistical outcomes, although it is very
difficult to conduct controlled trials in IE
patients. All patients with at least one dose of
daptomycin were included, however, it should
be noted that the correct course of treatment for
daptomycin lasts between 4 and 6 weeks. Some
patients included in the registry might have
received other antibiotics besides daptomycin.
CONCLUSIONS
These results of real-world experience from the
EU-CORE registry showed that patients with IE
were treated successfully with daptomycin.
Daptomycin was well tolerated and effective
for the treatment of LIE and BRLIE in addition
to the approved indication of RIE, which
provides evidence that daptomycin is a
potential treatment option in the
management of RIE, LIE and BRLIE. Data
showed that daptomycin is effective for
treating Gram-positive infections, including
MRSA infections. The majority of patients with
available long-term data remained relapse free
during the 2-year follow-up period.
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